Skip to main content

Advertisement

Table 4 Dichotomized distribution of MPO and IL-17 according to defined cut-offs (22 cells/punch for MPO and 1 cell/punch for IL-17 [27] in recurrent carcinomas (n = 45)a

From: MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity

  MPO-/IL17- n = 23 (100 %) MPO+/IL17- n = 4 (100 %) MPO-/IL17+ n = 12 (100 %) MPO+/IL17+ n = 6 (100 %) p-value
Age (median, range) 62 (47–77) 59.5 (45–69) 59 (34–68) 54.5 (39–60) 0.277
FIGO stage
 II 0 0 1 (8.3) 0 0.574
 IIIA 0 0 1 (8.3) 0
 IIIB 2 (8.7) 0 2 (16.7) 1 (16.7)
 IIIC 17 (73.9) 4 (100.0) 6 (50.0) 3 (50.0)
 IV 4 (17.4) 0 2 (16.7) 2 (33.3)
Residual disease
 None 7 (30.4) 0 6 (50.0) 2 (33.3) 0.046
 <2 cm 5 (21.7) 3 (66.7) 5 (41.7) 4 (66.7)
 >2 cm 10 (43.5) 1 (33.3) 1 (8.3) 0
Numbers of chemotherapy cycles
 <6 3 (13.0) 0 3 (25.0) 1 (16.7) 0.806
 6 or more 19 (82.6) 4 (100.0) 9 (75.0) 5 (83.3)
CSb 13 (56.5) 3 (66.7) 10 (83.3) 6 (100.0) 0.123
CRb 10 (43.5) 1 (33.3) 2 (16.7) 0
RFSc (mean/SE) 7.7 (1.8) 12.5 (7.1) 14.2 (2.5) 8.3 (2.2) 0.121
OSc (mean/SE) 33.5 (5.8) 20 (2.0) 53.4 (9.3) 45.2 (6.5) 0.074
  1. Bold data statistically significant p < 0.05
  2. apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Fisher’s Exact test
  3. bCS chemosensitive, CR chemoresistant
  4. cRFS recurrence-free survival, OS overall survival